Chimeric antigen receptor (CAR)-T
Jul 30, 2024
The Changing Landscape of Multiple Myeloma Therapies Market
Multiple Myeloma, the second most common type of blood cancer after non-Hodgkin lymphoma, is characterized by the presence of malignant plasma cells in the bone marrow. The diagnosis involves identifying these highly abnormal and unstable cells, which proliferate aggressively and spread through the bloodstream and ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
